ENABLE Biotech aims to partner with companies from research to clinical stage to address specific challenges of manufacturing Advanced Therapies.

Our next generation CDMO model enables an attractive pricing structure and expertise in CMC for speed to Phase I/IIa.

Products, services, technology

Autologous and Allogeneic Gene-modified Cell Therapy & Exosome therapies including PBMC (T Cells, NK cells, Invariant NK Cells) iPSC, MSC, HLSC, etc.

Phase adapted CMC Expertise in CGT.

Support from Tech Transfer to Process Development and Scale-up to Pre-clinical and clinical GMP manufacturing.

Cooperation possibilities

Located at the heart of the European market, Enable Biotech is the right partner for early stage Advanced Therapy biotechs and academic spin-offs.

We have available capacity for development and GMP manufacturing of R&D up to Phase I/IIa Cell therapy, Exosome, Gene modified cell therapy


Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in